With a market cap. of $37.3 billion, GE HealthCare Technologies Inc. (GEHC) is a leading global healthcare solutions provider offering advanced medical technology, pharmaceutical diagnostics, and AI, cloud, and software solutions to help clinicians address complex diseases. With 130 years of experience, approximately 54,000 employees, and $20.6 billion in annual business, the company operates through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments, focusing on innovations that enable more personalized and precise patient care.
Shares of the medical technology company have underperformed the broader market over the past 52 weeks. GEHC stock has risen 9.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 11.5%. Moreover, shares of the company are up marginally on a YTD basis, compared to SPX’s 11.6% gain.
Focusing more closely, shares of the Chicago, Illinois-based company have lagged behind the State Street Health Care Select Sector SPDR ETF’s (XLV) 23.5% gain over the past 52 weeks.
GE HealthCare shares rose 6.6% on Oct. 28 following better-than-expected Q3 2026 results, with revenue increasing 7.2% to $5.5 billion, organic revenue growth of 6.2%, and adjusted EPS climbing 25.1% to $1.34. Profitability also improved significantly, as adjusted EBIT increased to $913 million and adjusted EBIT margin expanded 180 basis points to 16.6%, while net income rose to $615 million and EPS jumped 39.1% to $1.36. \
Investor sentiment was further boosted by the company's decision to raise its 2026 adjusted EPS guidance to $4.95 - $5.05, lift its organic revenue growth outlook to approximately 4%, and increase its free cash flow forecast to at least $1.6 billion.
For the fiscal year ending in December 2026, analysts expect GEHC’s adjusted EPS to grow 9.4% year-over-year to $5.02. The company's earnings surprise history is mixed. It beat the consensus estimates in three of the last four quarters while missing on another occasion.
Among the 23 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on 12 “Strong Buy” ratings, three “Moderate Buys,” and eight “Holds.”
This configuration is slightly more bullish than three months ago, with 11 “Strong Buy” ratings on the stock.
On Nov. 11, Argus raised its price target on GE HealthCare to $110 and maintained a “Buy” rating.
The mean price target of $87.87 represents a 6.8% premium to GEHC’s current price levels. The Street-high price target of $110 suggests a 33.6% potential upside.
On the date of publication, Sohini Mondal did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.